NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Consensus Rating of “Hold” by Analysts

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have been given a consensus rating of “Hold” by the six analysts that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $36.75.

Several equities research analysts have commented on NRXP shares. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. D. Boral Capital restated a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, February 17th. BTIG Research reaffirmed a “buy” rating and set a $25.00 target price on shares of NRx Pharmaceuticals in a research note on Wednesday, February 18th. Ascendiant Capital Markets reissued a “buy” rating and issued a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Finally, Zacks Research lowered NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th.

NRx Pharmaceuticals Stock Down 3.6%

NRXP stock opened at $1.86 on Friday. The stock has a market cap of $59.28 million, a PE ratio of -0.79 and a beta of 1.91. The firm’s 50-day simple moving average is $2.15 and its 200 day simple moving average is $2.52. NRx Pharmaceuticals has a fifty-two week low of $1.58 and a fifty-two week high of $3.84.

Institutional Trading of NRx Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Ethos Financial Group LLC bought a new position in shares of NRx Pharmaceuticals in the third quarter valued at approximately $39,000. Sjbenen Advisory LLC acquired a new stake in NRx Pharmaceuticals in the fourth quarter worth approximately $41,000. One Wealth Management Investment & Advisory Services LLC lifted its position in NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after purchasing an additional 12,950 shares during the period. Global Retirement Partners LLC bought a new position in NRx Pharmaceuticals during the 4th quarter valued at $107,000. Finally, Two Sigma Investments LP increased its position in shares of NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares during the period. 4.27% of the stock is currently owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.